| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Net loss | -839,853 | -1,090,561 | -4,631,655 | NaN |
| Depreciation expense | 2,351 | 2,178 | 2,649 | 4,026 |
| Amortization of intangibles | 17,103 | 16,976 | 17,455 | 34,910 |
| Stock based compensation | 256,683 | 99,168 | 363,083 | 490,465 |
| Employees paid in stock | 55,479 | 435,199 | 0 | 293,551 |
| Expense paid in stock | NaN | 819,422 | 0 | 201,251 |
| Bad debt expense | 4,014 | 3,114 | 0 | 8,525 |
| Net loss | NaN | NaN | NaN | -3,477,696 |
| Amortization of right-of-use asset | 28,579 | 31,133 | 18,974 | 57,356 |
| (increase ) decrease in advances on contracts | NaN | 133,134 | NaN | NaN |
| Decrease (increase) in accounts receivable | -120,840 | -23,190 | 22,723 | 217,350 |
| Decrease (increase) in prepaid expenses and other current assets | NaN | -168,791 | NaN | 72,938 |
| Decrease (increase) in accounts receivable, related parties | -3,211 | 15,936 | 3,183 | 6,429 |
| Decrease (increase) in inventories | -290,324 | -345,151 | 229,971 | 183,802 |
| (increase) decrease in advances on contracts | -136,052 | NaN | 283,418 | -143,976 |
| Increase in deferred financing costs | 332,671 | NaN | NaN | NaN |
| Increase in prepaid expenses and other current assets | 266,099 | NaN | -58,071 | NaN |
| Increase in accounts payable | 839,046 | -582,618 | 562,282 | 429,192 |
| (decrease) increase in accounts payable, related party | -366,824 | 332,339 | 521,905 | 12,142 |
| Increase (decrease) in accrued expenses | 58,329 | -184,690 | -208,890 | -407,536 |
| Increase in accrued expenses, related party | -188,563 | 474,364 | -333,369 | -25,108 |
| Decrease operating right of use lease asset | 26,914 | 29,920 | 17,023 | 56,808 |
| Net cash provided by (used in) operating activities | 86,842 | -226,129 | 81,775 | -2,772,273 |
| Sale of marketable securities | NaN | NaN | NaN | 0 |
| Purchase of furniture, fixtures, and equipment | 1,632 | 3,116 | 6,232 | 5,776 |
| Net cash used in investing activities | -1,632 | -3,116 | -6,232 | -5,776 |
| Proceeds exercise of warrants | NaN | NaN | NaN | 0 |
| Proceeds from issuance of convertible notes, related parties-Public Placement Offering Debt | NaN | NaN | NaN | 800,000 |
| Net proceeds from public placement offering-Public Offering | NaN | NaN | NaN | 0 |
| Proceeds from issuance of convertible notes, related parties | NaN | 0 | 800,000 | NaN |
| Payments finance lease obligations | 3,428 | 3,414 | 4,556 | 5,695 |
| Net cash used in financing activities | -3,428 | -3,414 | -4,556 | 794,305 |
| Net increase (decrease) in cash and cash equivalents | 81,782 | -232,659 | 70,987 | -1,983,744 |
| Cash and cash equivalents at beginning of period | 1,112,642 | 1,345,301 | 3,258,058 | NaN |
| Cash and cash equivalents at end of period | 1,194,424 | 1,112,642 | 1,345,301 | NaN |
MILESTONE SCIENTIFIC INC. (MLSS)
MILESTONE SCIENTIFIC INC. (MLSS)